Stockreport

LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to announce that the Company and NantCell, Inc. ("NantCell [Read more]